Table 3.

Warfarin treatment by HAS-BLED and CHADS2 score

		60–69 years				70–79 years				80+ years (reference group)
CHADS2	Age group	Patients n	Patients treated with warfarin (%)	χ2 Value*	p Value*	Patients n	Patients treated with warfarin (%)	χ2 Value†	p Value†	Patients n	Patients treated with warfarin (%)
0	HAS-BLED > CHADS2	4265	49	–	–	3998	51	–	–	0	–
	HAS-BLED≤CHADS2	1978	49	–	–	0	–	–	–	0	–
1	HAS-BLED>CHADS2	2880	56	692	<0.0001	5556	52	697	<0.0001	3801	25
	HAS-BLED≤CHADS2	3821	60	814	<0.0001	4309	56	640	<0.0001	4492	29
2	HAS-BLED>CHADS2	512	55	130	<0.0001	2296	52	266	<0.0001	3286	30
	HAS-BLED≤CHADS2	2137	65	772	<0.0001	6997	58	1022	<0.0001	10596	33
3	HAS-BLED>CHADS2	128	52	31	<0.0001	419	53	71	<0.0001	526	26
	HAS-BLED≤CHADS2	965	69	419	<0.0001	4157	58	554	<0.0001	6524	34
4+	HAS-BLED>CHADS2	7	57	3	0.0762	62	53	13	0.0004	111	26
	HAS-BLED≤CHADS2	361	66	129	<0.0001	2556	57	286	<0.0001	4641	36

*χ² tests comparing the proportion of patients treated with warfarin in the 60–69 years age group compared with the 80+ years age group.

†χ² tests comparing the proportion of patients treated with warfarin in the 70–79 years age group compared with the 80+ years age group.